MannKind (MNKD) said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.
The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.
No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.
MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.